Total Payments
$269,149
2024 Payments
$31,654
Companies
3
Transactions
56
Medicare Patients
8,585
Medicare Billing
$420,593
Payment Breakdown by Category
Research$244,629 (90.9%)
Consulting$24,520 (9.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $244,629 | 16 | 90.9% |
| Consulting Fee | $24,520 | 40 | 9.1% |
Payments by Type
Research
$244,629
16 transactions
General
$24,520
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $212,975 | 15 | $0 (2019) |
| AMAG Pharmaceuticals, Inc. | $31,654 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $24,520 | 40 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,654 | 1 | AMAG Pharmaceuticals, Inc. ($31,654) |
| 2021 | $1,040 | 4 | Merck Sharp & Dohme Corporation ($1,040) |
| 2020 | $2,795 | 9 | Merck Sharp & Dohme Corporation ($2,795) |
| 2019 | $56,685 | 15 | E.R. Squibb & Sons, L.L.C. ($52,575) |
| 2018 | $95,555 | 16 | E.R. Squibb & Sons, L.L.C. ($89,050) |
| 2017 | $81,420 | 11 | E.R. Squibb & Sons, L.L.C. ($71,350) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/14/2024 | AMAG Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $31,653.60 | Research |
| 12/20/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| Category: ONCOLOGY | ||||||
| 02/18/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $325.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| Category: ONCOLOGY | ||||||
| 03/02/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 12/26/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $265.00 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $65.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1 2 Study of the Combination of Lirilumab Anti KIR Plus Nivolumab Anti PD 1 or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors | E.R. Squibb & Sons, L.L.C. | $59,125 | 3 |
| An Open Label Randomized Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen Cetuximab Cisplatin Carboplatin Fluorouracil as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and | E.R. Squibb & Sons, L.L.C. | $44,575 | 2 |
| A Double Blind Randomized Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $44,325 | 2 |
| An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen Cetuximab CisplatinCarboplatin Fluorouracil as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $37,050 | 1 |
| A Phase I 2a Dose Escalation and Cohort Expansion Study of the Safety Tolerability and Efficacy of Anti LAG 3 Monoclonal Antibody BMS 986016 Administered Alone and in Combination With Anti PD 1 Monoclonal Antibody Nivolumab BMS 936558 in Advanced Solid Tu | E.R. Squibb & Sons, L.L.C. | $12,225 | 3 |
| A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $10,950 | 1 |
| A Phase I2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody BMS-986016 Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558 in Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $3,900 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck SCCHN | E.R. Squibb & Sons, L.L.C. | $675.00 | 1 |
| A Randomized Double blind Placebo controlled Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and | E.R. Squibb & Sons, L.L.C. | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,216 | 2,339 | $606,883 | $105,594 |
| 2022 | 16 | 2,261 | 2,388 | $618,888 | $109,676 |
| 2021 | 14 | 2,169 | 2,301 | $566,160 | $107,690 |
| 2020 | 16 | 1,939 | 2,043 | $491,831 | $97,633 |
Total Patients
8,585
Total Services
9,071
Medicare Billing
$420,593
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 952 | 1,060 | $195,305 | $33,671 | 17.2% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 167 | 168 | $82,614 | $14,535 | 17.6% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 201 | 203 | $64,509 | $11,479 | 17.8% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 301 | 306 | $69,241 | $11,428 | 16.5% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 107 | 108 | $40,575 | $7,297 | 18.0% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 99 | 99 | $37,197 | $6,585 | 17.7% |
| 72131 | Ct scan of lower spine without contrast | Facility | 2023 | 87 | 90 | $19,398 | $3,418 | 17.6% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 53 | 53 | $16,840 | $3,033 | 18.0% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 22 | 22 | $10,815 | $2,090 | 19.3% |
| 70486 | Ct scan of face without contrast | Facility | 2023 | 56 | 57 | $13,190 | $1,775 | 13.5% |
| 72128 | Ct scan of middle spine without contrast | Facility | 2023 | 45 | 46 | $9,900 | $1,770 | 17.9% |
| 72141 | Mri scan of upper spinal canal without contrast | Facility | 2023 | 29 | 29 | $9,210 | $1,708 | 18.5% |
| 72156 | Mri scan of upper spinal canal before and after contrast | Facility | 2023 | 16 | 16 | $7,866 | $1,491 | 19.0% |
| 72158 | Mri scan of lower spinal canal before and after contrast | Facility | 2023 | 13 | 13 | $6,392 | $1,124 | 17.6% |
| 72157 | Mri scan of middle spinal canal before and after contrast | Facility | 2023 | 11 | 12 | $5,900 | $1,104 | 18.7% |
| 70549 | Mri scan of blood vessels of neck before and after contrast | Facility | 2023 | 14 | 14 | $5,404 | $1,016 | 18.8% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2023 | 15 | 15 | $4,458 | $747.63 | 16.8% |
| 70544 | Mri scan of blood vessels of head without contrast | Facility | 2023 | 14 | 14 | $3,620 | $673.24 | 18.6% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 14 | 14 | $4,449 | $648.54 | 14.6% |
| 70450 | Ct scan head or brain without contrast | Facility | 2022 | 962 | 1,076 | $194,356 | $34,298 | 17.6% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2022 | 233 | 235 | $112,920 | $20,921 | 18.5% |
| 70551 | Mri scan of brain without contrast | Facility | 2022 | 224 | 226 | $70,108 | $12,661 | 18.1% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2022 | 257 | 265 | $59,885 | $9,988 | 16.7% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2022 | 89 | 89 | $32,639 | $5,644 | 17.3% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2022 | 82 | 82 | $30,095 | $5,205 | 17.3% |
About Dr. Juan Small, MD
Dr. Juan Small, MD is a Diagnostic Radiology healthcare provider based in Burlington, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467528950.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Juan Small, MD has received a total of $269,149 in payments from pharmaceutical and medical device companies, with $31,654 received in 2024. These payments were reported across 56 transactions from 3 companies. The most common payment nature is "" ($244,629).
As a Medicare-enrolled provider, Small has provided services to 8,585 Medicare beneficiaries, totaling 9,071 services with total Medicare billing of $420,593. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Burlington, MA
- Active Since 11/27/2006
- Last Updated 03/04/2011
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1467528950
Products in Payments
- OPDIVO (Biological) $137,725
- KEYTRUDA (Biological) $24,520
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Burlington
Miklos Marosfoi, Md, MD
Diagnostic Radiology — Payments: $296,146
Diagnostic Radiology $296,146
David Rosman, M.d, M.D
Diagnostic Radiology — Payments: $117,880
Diagnostic Radiology $117,880
Neil Patel, M.d, M.D
Diagnostic Radiology — Payments: $24,691
Diagnostic Radiology $24,691
Dr. Jeanette Chun, M.d, M.D
Diagnostic Radiology — Payments: $19,050
Diagnostic Radiology $19,050
Bill Majdalany, M.d, M.D
Diagnostic Radiology — Payments: $18,165
Diagnostic Radiology $18,165
Francis Scholz, M.d, M.D
Diagnostic Radiology — Payments: $17,832
Diagnostic Radiology $17,832